AR and prostate carcinoma: The small molecule compound ET516 inhibits the formation of LLPS of wild-type and drug-resistant mutant androgen receptor (AR), which in turn inhibits the transcriptional activity of AR, and ultimately suppresses the tumor growth of prostate cancer cells expressing drug-resistant mutant AR in vivo (182).